BACKGROUND: Achieving significant weight loss and glycemic control in diabetic patients remains a challenging task. OBJECTIVE: This study compared the effects of a soy-based meal replacement (MR) plan vs an individualized diet plan (IDP; as recommended by the American Diabetes Association) on weight loss and metabolic profile. DESIGN/ SUBJECTS:A total of 104 subjects were randomized prospectively to the two treatments for a total of 12 months. RESULTS: In all, 77 of the 104 subjects completed the study. Percentage weight loss in MR group (4.57+/-0.81%) was significantly greater (P<0.05) than in IDP group (2.25+/-0.72%). Fasting plasma glucose was significantly reduced in MR group (126.4+/-4.9 mg/dl) compared with IDP group (152.5+/-6.6 mg/dl, P<0.0001) at 6 months but not at 12 months. Controlling for baseline levels, hemoglobin Alc level improved by 0.49+/-0.22% for those receiving MR when compared to IDP group (P<0.05). A greater number of subjects in MR group reduced their use of sulfonylureas (P<0.0001) and metformin (P<0.05) as compared to IDP group. High-sensitivity C-reactive protein (hs-CRP) decreased -26.3% (P = 0.019) in MR group compared to -7.06% (P = 0.338) in IDP group at 6 months. Similar changes were observed at 12 months with MR groups, with hs-CRP decreasing by -25.0% (P = 0.019) compared to -18.7% (P = 0.179) in IDP group. CONCLUSION: This study demonstrates that MR is a viable strategy for weight reduction in diabetic patients, resulting in beneficial changes in measures of glycemic control and reduction of medications.
RCT Entities:
BACKGROUND: Achieving significant weight loss and glycemic control in diabeticpatients remains a challenging task. OBJECTIVE: This study compared the effects of a soy-based meal replacement (MR) plan vs an individualized diet plan (IDP; as recommended by the American Diabetes Association) on weight loss and metabolic profile. DESIGN/ SUBJECTS: A total of 104 subjects were randomized prospectively to the two treatments for a total of 12 months. RESULTS: In all, 77 of the 104 subjects completed the study. Percentage weight loss in MR group (4.57+/-0.81%) was significantly greater (P<0.05) than in IDP group (2.25+/-0.72%). Fasting plasma glucose was significantly reduced in MR group (126.4+/-4.9 mg/dl) compared with IDP group (152.5+/-6.6 mg/dl, P<0.0001) at 6 months but not at 12 months. Controlling for baseline levels, hemoglobin Alc level improved by 0.49+/-0.22% for those receiving MR when compared to IDP group (P<0.05). A greater number of subjects in MR group reduced their use of sulfonylureas (P<0.0001) and metformin (P<0.05) as compared to IDP group. High-sensitivity C-reactive protein (hs-CRP) decreased -26.3% (P = 0.019) in MR group compared to -7.06% (P = 0.338) in IDP group at 6 months. Similar changes were observed at 12 months with MR groups, with hs-CRP decreasing by -25.0% (P = 0.019) compared to -18.7% (P = 0.179) in IDP group. CONCLUSION: This study demonstrates that MR is a viable strategy for weight reduction in diabeticpatients, resulting in beneficial changes in measures of glycemic control and reduction of medications.
Authors: Kimberly A Gudzune; Ruchi S Doshi; Ambereen K Mehta; Zoobia W Chaudhry; David K Jacobs; Rachit M Vakil; Clare J Lee; Sara N Bleich; Jeanne M Clark Journal: Ann Intern Med Date: 2015-04-07 Impact factor: 25.391
Authors: K M Beavers; M M Gordon; L Easter; D P Beavers; K G Hairston; B J Nicklas; M Z Vitolins Journal: J Nutr Health Aging Date: 2015-01 Impact factor: 4.075
Authors: Daniel R Christie; Jan Grant; Betty E Darnell; Victoria R Chapman; Amalia Gastaldelli; Cynthia K Sites Journal: Am J Obstet Gynecol Date: 2010-05-01 Impact factor: 8.661
Authors: Lisa M Davis; Christopher Coleman; Jessica Kiel; Joni Rampolla; Tammy Hutchisen; Laura Ford; Wayne S Andersen; Andrea Hanlon-Mitola Journal: Nutr J Date: 2010-03-11 Impact factor: 3.271
Authors: Katherine E Nori Janosz; Kerstyn C Zalesin; Wendy M Miller; Peter A McCullough; Barry A Franklin Journal: Curr Diab Rep Date: 2009-06 Impact factor: 4.810